Abstract:Introduction Natural Killer (NK) cells are a promising source for Chimeric Antigen Receptor (CAR) cell-based therapiesdue to their MHC independency for activation, intrinsic ability against tumor cells, rapid cytokine production, and low potential to cause graft-versus-host-disease. Conventional CARs only recognize cell surface antigens, sparing numerous intracellular tumor-associated antigens. MAGE-A4 intracellular antigen is highly expressed in different cancers and has low expression in normal tissues. Following its expression within cells, MAGE-A4 is presented on the cell surface in association with HLA-A*02, conferring a cancer-specific antigen profile. This project uses a TCR-like CAR, and an innovative human GITR signaling domain, developed by our collaborator, Prof. Shiku Hiroshi at Mie University. This CAR construct demonstrates the ability to recognize the intracellular tumor-associated antigen MAGE-A4 when presented by HLA-A*02 molecules. This anti-MAGE-A4 CAR is presently undergoing evaluation in a multi-institutional phase 1 study. Objectives The primary aim of this study is to create an off-the-shelf CAR-NK cell product, using the anti-MAGE-A4 CAR, designed to target the HLA-A*02 complex along with a specific epitope of the MAGE-A4 antigen and to and to evaluate the therapeutic efficiency of these cells in the treatment of MAGE-A4+ solid tumors including melanoma. Material and methods LentiX-HEK293T cells were transfected with MAGE-A4 CAR DNA and helper plasmids to produce LV viral particles. K562 cell line were used for viral titration. NK-92 cell line were transduced using lentivirus particles with MOIs 10, 5, and 3. After 48 hours, the cells were evaluated by flow cytometry for CAR expression. Subsequently, anti-MAGE-A4 CAR NK-92 positive cells were enriched using magnetic beads. Meanwhile, target cell lines A375-Luc (MAGE-A4+), and HCT116-Luc (MAGE-A4-) were evaluated for MAGE-A4 expression by flow cytometry. To measure the specificity and cytotoxicity of anti-MAGE-A4 CAR NK-92, these cells were co-cultured with target cell lines expressing luciferase at different effector to target ratios. Cytotoxicity-mediated killing was assessed using bioluminescence-imaging systems (IVIS), quantifying the decrease of luminescence from baseline. Results We conducted NK cell transduction using MOIs of 10, 5, and 3. Our observations revealed transduction efficiencies of 52%, 49.1%, and 48.7% respectively. Next, CAR positive cells were selected and the percentage of anti-MAGE-A4 CAR-NK-92 cells increased to 99.4% and these cells were used for co-culture with target cell lines. The results of MAGE-A4 expression in A375 cell line was 68.6%, and 2.54% in HCT116. The cytotoxicity of anti-MAGE-A4 CAR-NK-92 effector cells against A375 target cell line is around 80% in the ratio of 1:1 and 5:1. MAGE-A4-CAR-NK cells demonstrated enhanced effectiveness in killing A375 cells when compared to NK92-WT cells (p < 0.05), underscoring the specificity of the CAR vector. Discussion Previous Studies done by Dr. Shiku team have already demonstrated the effectiveness of TCR-like CAR-T cells against MAGE-A4+ tumors. Our study is the first to demonstrate the effectiveness of this anti-MAGE-A4 CAR incorporating GITR as a costimulatory domain in NK cells. Conclusion This study has the potential to create a new off-the-shelf advanced cell therapy approach against MAGE-A4+ malignancies.

Novel Human NK Cell Line Carrying CAR Targeting EGFRvIII Induces Antitumor Effects in Glioblastoma Cells

KHYG-1 Cells With EGFRvIII-specific CAR Induced a Pseudoprogression-like Feature in Subcutaneous Tumours Derived from Glioblastoma-like Cells

CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells

Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth

Abstract 3313: iPSC-derived natural killer cells expressing EGFR-CAR against glioblastoma

High-Affinity Chimeric Antigen Receptor With Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms

Abstract B034: Assessing the cytotoxic potential of novel CAR-NK cells targeting glioblastoma stem cell antigens

Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma

10172-IM-6 DEVELOPMENT OF CAR-NK CELL THERAPY TARGETING B7H3 AGAINST GLIOBLASTOMA

CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy

Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice

EGFRvIII-Specific Chimeric Antigen Receptor T Cells Migrate to and Kill Tumor Deposits Infiltrating the Brain Parenchyma in an Invasive Xenograft Model of Glioblastoma

IMMU-18. ESTABLISHMENT OF CAR-NK CELL THERAPY TARGETING B7-H3 AGAINST GLIOBLASTOMA

MAGE-A4-CAR-NK CELL THERAPY FOR THE TREATMENT OF SOLID TUMORS

Antitumor effects of intracranial injection of B7-H3-targeted Car-T and Car-Nk cells in a patient-derived glioblastoma xenograft model

Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma

SYST-12 D2C7 CAR: A NOVEL CAR T CELL THAT SIMULTANEOUSLY TARGETS WILDTYPE EGFR AND ITS MUTANT ISOFORM EGFRVIII FOR TREATMENT OF GLIOMA AND BRAIN METASTASES

Ctim-04. Modulation Of The Intratumoral Immune Microenvironment By Local Therapy With Natural Killer Cells Engineered With A Her2-Targeted Chimeric Antigen Receptor In Combination With Systemic Anti-Pd-1 Checkpoint Inhibition In Patients With Recurrent Glioblastoma

Abstract 2907: Development of a CAR-NK cellular platform for cancer immunotherapy

Non–clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell‐derived anti–glypican‐3 chimeric antigen receptor‐expressing natural killer/innate lymphoid cells

Development and characterisation of NKp44-based chimeric antigen receptors that confer T cells with NK cell-like specificity